SurModics (SRDX) Misses Q2 EPS by 1c, Revenues Beat; Offers FY21 EPS Guidance Below Consensus, FY21 Revs. Mid-Point View Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to SurModics (SRDX) Misses Q2 EPS by 1c, Revenues Beat; Offers FY21 EPS Guidance Below Consensus, FY21 Revs. Mid-Point View Above Consensus

Surmodics Reports Second Quarter Fiscal 2021 Results and Issues Fiscal 2021 Revenue and EPS Guidance

April 28, 2021 7:30 AM EDT

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 second quarter ended March 31, 2021 and provided its financial outlook for its fiscal 2021.

Summary of Second Quarter and Recent Highlights

Revenue of $35.0 million, an increase of 53% year-over-year GAAP EPS of $0.58, non-GAAP EPS of $0.62 Successful first patient uses of two Sublime radial access platform devices Recognized $10.8 million in license fee revenue upon receipt of $15 million... More